Biotechnology company Alloy Therapeutics acquires deepCDR Biologics
Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation.
Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire additional computational scientists and developers as it grows with the Alloy network.
DeepCDR’s technology will strengthen Alloy Discovery Services capabilities with patent-pending machine learning-powered antibody repertoire screening, in silico library screening, and mammalian display. DeepCDR thoughtfully integrates wet lab antibody screening and characterisation with the computational tools to enable a powerful learning loop generating real world results.
Walder Wyss acted as Swiss legal counsel for Alloy Therapeutics. The team comprised Alexander Gutmans (partner, corporate/m&a and venture capital, pictured), Michelle Bruni (senior associate, corporate/m&a and tax), Karina Tschon (associate, corporate/m&a and venture capital) as well as Bojan Momic (associate, employment).
Vischer has been advising deepCDR Biologics since foundation as well as on all legal issues related to the sale to Alloy Therapeutics. The Vischer team includes partner Matthias Staehelin working alongside associates Pauline Pfirter and Timothy Woodtli (all corporate/m&a).
